Rare diseases
Investigational molecules
Locations
706 conditions with trials, the busiest first
3 924 trials across Europe, recruiting first
Efficacy of asciminib in chronic phase chronic myeloid leukemia patients with T315I mutation
GermanyEvaluation of recurrence‑free survival with cemiplimab immunotherapy in medically inoperable stage I non‑small cell lung cancer patients
The NetherlandsPhase 2 Study of Durvalumab + Tremelimumab with Lenvatinib vs Durvalumab + Tremelimumab Alone in Patients with Unresectable Hepatocellular Carcinoma
ItalyRandomized phase III adjuvant capecitabine plus temozolomide versus surveillance in patients with resected stage I‑III pancreatic neuroendocrine tumors
FranceLong‑term safety study of S68587 (allogeneic CD19 CAR T‑cells with TRAC and CD52 disruption) in patients with advanced lymphoid leukemia
FranceRadium-223 dichloride (223RaCl) with drug combination for patients with symptomatic bone metastases from breast cancer
Italy
DenmarkDiagnostic Accuracy of [18F]FAPI-74 PET/CT for Detecting Metastasis and Assessing Treatment Response in Gastric Cancer Patients
FinlandPostoperative oxaliplatin liver‑directed chemotherapy plus drug combination in patients with resected colorectal liver metastases at high risk of recurrence
FrancePhase I/II Study of ubamatamab plus drug combination in patients with ovarian cancer who have poor response to first‑line chemotherapy
FrancePrevention of radiation-induced salivary gland damage using botulinum toxin type A in patients with head and neck cancer
CzechiaEvaluation of V-Cu64 versus V-Ga68 PET-CT imaging in adults with diagnosed or suspected neuroendocrine tumors
PolandThe therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
